

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A pharmaceutical composition for the treatment of IL-6 related diseases, comprising an interleukin 6 antagonist (IL-6 antagonist) and an immunosuppressant.
2. (Withdrawn) A pharmaceutical composition comprising immunosuppressants, for effect enhancement on the use of IL-6 antagonist for the treatment of IL-6 related diseases.
3. (Withdrawn) A pharmaceutical composition comprising immunosuppressants, for the reduction or prevention of allergic reactions upon the treatment of IL-6 related diseases with an IL-6 antagonist.
4. (Withdrawn) A therapeutic agent for the administration at high doses, comprising an IL-6 antagonist.
5. (Withdrawn) A pharmaceutical composition comprising a high dose of IL-6 antagonist, for the reduction or prevention of allergic reactions upon the treatment of IL-6 related diseases.
6. (Withdrawn) The pharmaceutical composition according to claim 1, wherein said IL-6 antagonist is an anti-interleukin-6 receptor antibody (IL-6R antibody).
7. (Withdrawn) The pharmaceutical composition according to claim 6, wherein said IL-6R antibody is a monoclonal antibody against IL-6R.
8. (Withdrawn) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a monoclonal antibody against human IL-6R.
9. (Withdrawn) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a monoclonal antibody against mouse IL-6R.

10. (Withdrawn) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a recombinant antibody.
11. (Withdrawn) The pharmaceutical composition according to claim 8, wherein said human anti-IL-6R monoclonal antibody is PM-1 antibody.
12. (Withdrawn) The pharmaceutical composition according to claim 9, wherein said mouse IL-6R monoclonal antibody is MR16-1 antibody.
13. (Withdrawn) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a chimera antibody, a humanized antibody or a human type antibody against IL-6R.
14. (Withdrawn) The pharmaceutical composition according to claim 13, wherein said humanized antibody against IL-6R is humanized PM-1 antibody.
15. (Withdrawn) The pharmaceutical composition according to claim 1, wherein said IL-6 related diseases are rheumatoid arthritis, plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, multiple myeloma, Castleman's disease, mesangial proliferative nephritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, pancreatitis, psoriasis, juvenile idiopathic arthritis or systematic juvenile idiopathic arthritis, vasculitis and Kawasaki disease.
16. (Withdrawn) The pharmaceutical composition according to claim 6, which is said pharmaceutical composition comprising the immunosuppressant or said pharmaceutical composition comprising the antibody and the immunosuppressant, wherein a dosage of anti-IL-6R antibody is from 0.02 to 150 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.
17. (Withdrawn) The pharmaceutical composition according to claim 16, wherein the dosage of anti-IL-6R antibody is from 0.5 to 30 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

18. (Withdrawn) The pharmaceutical composition according to claim 17, wherein the dosage of anti-IL-6R antibody is from 2 to 8 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.
19. (Withdrawn) The pharmaceutical composition according to claim 4, which is said therapeutic agent for the treatment of IL-6 related diseases for the administration at high doses, comprising the anti-IL-6R antibody or said pharmaceutical composition comprising high doses of the anti-IL-6R antibody, wherein the dosage of anti-IL-6R antibody is 4 mg/kg/4 weeks or more or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.
20. (Withdrawn) The pharmaceutical composition according to claim 19, wherein the dosage of anti-IL-6R antibody is from 6 to 16 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.
21. (Withdrawn) The pharmaceutical composition according to claim 20, wherein the dosage of anti-IL-6R antibody is from 6 to 10 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.
22. (Withdrawn) The pharmaceutical composition according to claim 1, wherein said immunosuppressant is methotrexate (MTX).
23. (Withdrawn) The pharmaceutical composition according to claim 22, wherein the dosage of said MTX is from 1 to 100 mg/body/week.
24. (Withdrawn) The pharmaceutical composition according to claim 23, wherein the dosage of said MTX is from 4 to 50 mg/body/week.
25. (Withdrawn) The pharmaceutical composition according to claim 24, wherein the dosage of said MTX is from 7.5 to 25 mg/body/week.
26. (Withdrawn) The pharmaceutical composition according to claim 1, for simultaneously administering said anti-IL-6 antibody and said immunosuppressant.

27. (Withdrawn) The pharmaceutical composition according to claim 1, for administering said anti-IL-6 antibody and said immunosuppressant with time interval.

28. – 54. (Cancelled)

55. **(Currently Amended)** A method for treating rheumatoid arthritis ~~an IL-6 related disease~~, comprising administering an effective amount of an anti-IL-6 receptor antibody (anti-IL-6R antibody) ~~that inhibits binding of IL-6 to the IL-6 receptor by binding to the IL-6 receptor to block signaling of IL-6 biological activity into cells,~~ and an effective amount of methotrexate (MTX) to a patient in need thereof ~~requiring such a treatment~~, wherein the anti-IL-6R antibody is a humanized PM-1 antibody ~~said IL-6 related disease is rheumatoid arthritis.~~

56. - 83. (Cancelled)